Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation. While improvements in immunosuppressive regimens have reduced the frequency and severity of acute GVHD, the incidence of chronic GVHD remains unchanged at 27-50% after sibling matched related donor transplants and 42-72% after unrelated donor bone marrow or peripheral blood stem cell transplanted. [1] [2] [3] [4] [5] [6] Factors associated with cGVHD have been well-described and include increased donor and recipient age, HLA-disparate and unrelated donor transplants, prior acute GVHD, and use of alloimmune female donors. 7, 8 The onset of cGVHD has arbitrarily been defined as occurring 100 days after allogeneic stem cell infusion, and its clinical features are distinguished from acute GVHD in that they more closely resemble autoimmune diseases. 7, 8 Correspondence: Dr FM Foss, Bone Marrow Transplantation and Experimental Therapeutics, Tufts New England Medical Center, Boston, MA 02111, USA Histopathologic changes which include sclerodermatous skin changes resulting from collagen deposition, pulmonary fibrosis, esophageal dysfunction, dry mouth or mucocutaneous ulcerations, cholestasis and myositis or fasciitis are thought to be initiated, in part, by autoantibodies to cell surface and intracellular proteins. 9 Conventional therapeutic approaches for cGVHD, including corticosteroids and immunosuppressive agents have demonstrated limited efficacy in patients with extensive disease. Ultraviolet A therapy (PUVA), while effective in alleviating the symptoms of chronic skin GVHD, has had no impact on visceral involvement. [10] [11] [12] [13] Novel strategies, including humanized anti-CD25 antibody (dacluzimab) and and anti-TNF-␣ antibody (infliximab), have shown promise in limited pilot studies.
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Extracorporeal phototherapy
Extracorporeal phototherapy (ECP) is an immunotherapeutic modality that has demonstrated clinical efficacy in cutaneous T cell lymphoma/Sezary syndrome (CTCL), scleroderma, and other autoimmune disorders. ECP involves extracorporeal exposure of peripheral blood mononuclear cells to photoactivated 8-methoxypsoralen (8-MOP), followed by reinfusion of the treated cells. 8-MOP is a naturally occurring furocourarin that is biologically inert, unless exposed to ultraviolet A light, whereupon it becomes photoactivated and covalently binds and crosslinks DNA, leading to initiation of apoptosis. During a single treatment cycle of ECP, approximately 240 cc of buffy coat and 300 ml of plasma are collected into a buffy coat bag from six collection cycles. The cells are exposed to UVA at 2 Jcm 2 /cell beginning immediately after the first cells are collected. 18 Examination of the cells after UVA exposure and prior to reinfusion demonstrates that about 2-5% of the total circulating peripheral blood mononuclear cells undergo apoptosis. 18 An intravenous formulation of 8-MOP, UVADEX, allows direct instillation of the photosensitizing agent into the collected plasma and buffy coat ex vivo prior to UVA exposure.
ECP was initially developed by Edelson et al 19 as a therapy for patients with cutaneous T cell lymphoma with circulating Sezary leukemia cells. Response rates of up to 60% were reported in the initial study with a median time to response of 4-6 months, when the treatment was administered for 2 consecutive days each month. [20] [21] [22] In a retrospective analysis of 450 patients treated in the United States and Europe, response rates of 56% and 66%, respectively, were reported. Response rates were higher in patients with circulating clonal CD4 + /CD7 − Sezary cells and in those with an intact immune system as determined by a normal CD4/CD8 ratio. 23 The anti-tumor effect correlated with the appearance of CD8 + cytotoxic T cells in the peripheral blood as well as the cells infiltrating into cutaneous tumor and plaque lesions. While the absolute number of Sezary leukemia cells decreased in most patients during ECP, there was no significant long-term modulation of normal CD4 + T lymphocyte populations. Although the mechanisms are less clear, ECP has also demonstrated similar efficacy in a number of autoimmune disorders, including scleroderma, pemphigus vulgaris, rheumatoid arthritis, systemic lupus erythematosis, and solid organ allograft rejection (Table  1) . 22, [24] [25] [26] [27] [28] 
Mechanism of action of ECP: preclinical models
The mechanism of action of UVA-mediated immunomodulation was first described in mice exposed to ultraviolet A light in the presence of 8-MOP (PUVA). Immunosuppression was accompanied by a decrease in the number and function of epidermal Langerhans cells and alteration in cytokine production by keratinocytes. 13 The administration of 8-MOP and UVA irradiated spleen and bone marrow cells to mice receiving allografts resulted in a significant attenuation of GVHD compared to littermates who received non-UVA irradiated cells, demonstrating an effect of UVA exposure on effectors of alloreactivity. 29 In another study, using C57BL/6 × DBA/2)F1 (B6D2F1) mice which, when inoculated with parental DBA/2 (D2) splenocytes, develop Table 1 Extracorporeal phototherapy: advantages, toxicities, uses and results 30 These results supported the concept that photoactivated T cells might be responsible for induction of a vaccine-like effect, although the putative anti-idiotype T cell populations have not been fully characterized.
Diseases in which ECP has been used
Effects of ECP on lymphocytes, monocytes and dendritic cells
The anti-idiotype response to clonal T cell populations induced by ECP is likely to be induced by UVA-mediated cellular damage. 31 T lymphocytes appear to be most sensitive to this effect, as demonstrated by Yoo et al, 32 who showed that normal T cell and Sezary T leukemia cells, but not other mononuclear populations, demonstrated morphologic evidence of apoptosis within 24 h after ECP treatment. In this study, 8-MOP alone failed to induce apoptosis, but exposure to UVA alone was associated with induction of early markers of apoptosis, including Annexin V. 18 Failure to detect apoptotic lymphocytes from 1-24 h after ECP may be related to uptake and clearance of these cells by the reticuloendothelial system. 32 In addition to initiating DNA strand breaks, upregulation of FAS expression on T lymphocytes may be another mechanism by which ECP induces apoptosis. Since T lymphocytes also express FAS ligand, self-induction of cell death may occur in the treated lymphocytes in the absence of cytokine secretion from monocytes or other accessory cells. 33 This may explain the observed selective effect of ECP on T lymphocytes, but not on B lymphocytes or mononuclear cells.
Selective effects of ECP on subpopulations of activated T cells have been observed in treated patients. Normalization of CD4/CD8 ratios has been described in CTCL patients, 34 as well as a shift from predominantly Th2 to Th1 cytokine secretion. In the context of CTCL, the restoration of Th1 cytokine secretion increases IL-12 production by monocytes, which might subsequently inhibit Th2 cytokine secreting cells that are believed to be responsible for the clinical manifestations of CTCL. 35 While monocytes appear to be resistant to the apoptotic effects of ECP, the induction of TNF-␣ secretion by photoactivated monocytes facilitates lymphocyte apoptosis. 36 Further, photoactivation of monocytes by ECP has also been shown to enhance their differentiation into CD83 +
CD36
+ dendritic cells capable of phagocytosing the apoptotic T cells. 37 In the presence of the costimulatory molecules, B7.1 and B7.2, these dendritic cells are capable of presenting tumor antigens from phagocytosed tumor cells in the context of MHC molecules and thus initiating cellular immune responses. 38 Upregulation of antigen presentation in concert with presence of exposure and processing of tumor antigens from apoptotic cells may explain why only those CTCL patients with circulating leukemia cells exhibited a clinical response to ECP. 
Clinical efficacy of ECP in cGVHD
A number of small studies have reported efficacy of ECP in GVHD (Table 2 ). Owsianowski et al 39 first reported improvement in lichenified skin changes, joint contractures, and sicca syndrome in one patient with chronic GVHD after starting ECP, with normalization of the CD4/CD8 ratio and increase in NK cells from 8 to 20%. Rosetti et al 40 subsequently reported improvement in skin, liver, and pulmonary GVHD in children, resulting in tapering or discontinuation of immunosuppressive. In this study, patients received ECP for 2 consecutive days every 3 weeks for 6 months, then monthly. Responders were noted to have a normalization of CD4/CD8 ratios and decrease in numbers of CD56 + Table 2 Studies of extracorporeal photopheresis in GVHD In two additional studies in adult patients, improvement was reported in sclerodermatous skin manifestations, but to a lesser degree in visceral sites such as mucocutaneous disease and liver involvement. 43 Two recent studies reported results of ECP in 11 and 15 patients, respectively. 44, 45 All patients had failed first-and second-line therapies, including corticosteroids and CsA. In one study ECP therapy was initiated late after the onset of cGVHD (median 510 days), while in the other it was initiated earlier (median 178 days). This difference may be relevant when comparing the outcomes of ECP in these two studies. In the group treated early, 12/15 patients had improvement in skin score, 11/11 in mucocutaneous dis-Bone Marrow Transplantation ease, 7/10 in hepatic enzymes, and 5/6 in ocular symptoms. In the group treated late after onset of cGVHD, response rate in the skin was still high (10/10 patients), but only 2/4 with oral and 1/5 with liver involvement demonstrated response in these visceral sites. In this group, the best responses in both skin and visceral disease were observed in patients who started ECP treatment less than 10 months from the time of BMT. A dose intensity effect was demonstrated in that improvement was greater over the first 4-6 months when patients were receiving ECP twice monthly.
Clinical improvement in patients treated with ECP on these studies enabled tapering of immunosuppressive agents and corticosteroids. The median time to discontinuation of corticosteroids was 80 days, and the median duration of response after discontinuation of ECP was 12 months, with 14% of patients experiencing a recurrence of symptoms of cGVHD after discontinuation. 45 Despite the need for intravenous access for ECP therapy in this group of immunocompromised patients, there was no increase in infection rate and no increase in reactivation of CMV infection.
ECP in acute GVHD
The largest series of patients with aGVHD treated with ECP was reported by Greinix et al, 46 who noted a 60% response rate in 21 patients with steroid refractory grades II-IV aGVHD. Patients were treated for 2 consecutive days at 1-to 2-week intervals until improvement and then every 2-4 weeks until maximal response. Complete responses were reported in all nine patients with grade II, 67% with grade III, and 12% with grade IV aGVHD. Responses were noted in the skin (60%) and liver (67%), but there were no responses in patients who had extensive involvement including skin, liver and gut. Corticosteroids were discontinued in the complete responders at a median of 53 days after initiation of ECP, and cyclosporin A was gradually tapered.
In this study, six patients died, five of infection and one from complications of gut GVHD. Of the responders, four developed cGVHD and eight are alive without cGVHD. The maximal response to ECP was observed after 2 months of therapy. In contrast to patients with cGVHD, patients treated early after stem cell infusion experienced thrombocytopenia, anemia and leukopenia associated with ECP therapy. There were no reported effects of ECP on establishment of the graft, but this remains an ongoing question as this therapy becomes more widely implemented in the early peritransplant period.
Immunomodulatory mechanisms of ECP in GVHD
Unlike CTCL, there are few data describing the impact of ECP on the underlying immunopathogenesis of cGVHD. While aGVHD is understood as a disease of acute alloreactivity, the etiology of cGVHD is controversial and is believed to be either an extension of aGVHD and/or a result of dysfunctional immune reconstitution with generation of autoantibodies and tissue auto-reactive T cell clones.
Further, cGVHD is a more heterogeneous disease than aGVHD, making interpretation of phase II clinical trial results difficult. Acute GVHD is believed to be a Th1-driven disease wherein inflammatory cytokines such as IL-2 and IFN␥ as well as the monokines IL1 and TNF␣, contribute to tissue damage. [47] [48] [49] In murine models, donor CD4-enriched cells of Th2 phenotype have been shown to prevent aGVHD without affecting engraftment, suggesting that they play a role in downregulating the Th1 response 50 and, in other studies, administration of a Th1 inhibitor (TAK-603) markedly reduced the mortality associated with aGVHD. 51 Chronic GVHD has been proposed by Ferrara and colleagues 52 to be a Th2-mediated disease, but recent studies demonstrating upregulation of Th1 cytokines IFN␥ and IL-12 in peripheral blood mononuclear cells implicate, in part, a Th1-driven mechanism similar to that seen in acute alloreactivity. 49, 52, 53 To elucidate the immunomodulatory effects of ECP on putative effectors of cGVHD, we initiated a clinical trial to evaluate lymphocyte and dendritic cell function in patients receiving ECP for 2 consecutive days every 2 weeks. 54 The median time from BMT in our population was 667 days (range, 101-600 days). Seven of 10 patients had a clinical response to ECP, with improvement in skin GVHD and joint contractures in patients with extensive sclerodermatous skin disease. Visceral improvement in ocular involvement was noted in 5/7, in oral GVHD in 5/8, and in liver in 2 of 3. Immunosuppressive therapy was decreased or discontinued in seven of 10 patients. In contrast to reports by Child et al, 44 who noted a lower response rate in patients who initiated ECP late in the course of cGHVD, four of five patients starting ECP therapy more than 10 months after BMT responded.
The detection of a clonal population of T cells in patients with scleroderma suggests that one explanation for the efficacy of ECP in this setting is induction of an antiidiotype response against host tissue-reactive T cell clones. When nine patients with cGVHD were analyzed for clonal populations of alloreactive T cells by spectratype analysis, we detected oligoclonal or monoclonal populations in seven. We observed a clinical response in all patients in whom clonal populations were detected. No clear monoclonal peaks were seen in two patients who did not respond to ECP. While the relevance of these monoclonal T cell populations in cGVHD patients has not been defined, ECP may generate an anti-idiotype response in cGVHD similar to its effect against Sezary leukemia cells and autoreactive clones in scleroderma.
Importance of antigen presenting cells in cGVHD pathogenesis
The most pronounced effect of ECP in our patients was a modulation of dendritic cell populations. In all responding patients, a 50% or greater decrease in circulating CD80 + and CD123
+ dendritic cell populations was noted with no marked change in CD28 expression on lymphocytes, suggesting no effect of ECP to modulate class I major histocompatibility complex-restricted T cell function. The decrease in antigen presenting cells paralleled a decrease in CD8
+ cells suggesting an overall suppression of alloreactivity. We further examined the effects of ECP on functional antigen presentation and found that after ECP, there was a significant attenuation of dendritic cell function, as measured by proliferation of allogeneic and autologous lymphocytes in a mixed lymphocyte reaction. These results suggest not only a decrease in numbers of DC1 dendritic cells, but also a direct effect of ECP on dendritic cell function.
Earlier reports demonstrated that UVA exposure in mice inhibits both the number and function of dendritic Langerhans cells in the skin, resulting in immune tolerance to allogeneic skin grafts. 55 The importance of antigen presenting cells in the initiation of chronic GVHD was demonstrated in a murine allogeneic bone marrow transplantation model in which it was demonstrated that the initial targets for CD8 + T cells in GVHD were restricted to proteins expressed by residual host antigen presenting dendritic cells. 56 When host dendritic cells were eradicated by conditioning or replaced with donor dendritic cells, thus decreasing the interaction between host antigen-presenting cells and donor CD8
+ cells, GVHD was attenuated. The immunomodulatory effects of ECP on effectors of GVHD are summarized in Table 3 .
A direct effect of ECP on dendritic cell number and/or function would lead to a decrease in alloantigen recognition, processing, and thus stimulation of CD8 + immune effectors or a Th1 response. This inhibition might be synergized by concordant effects on T cells to induce a shift from Th1 to Th2 cytokine profiles.
Based on these results, we propose that the mechanism of ECP in cGVHD is to alter alloreactivity by affecting both allo-targeted effector T cells, as well as the antigenpresenting machinery. While this proposed mechanism is contrary to what has been observed in CTCL patients in whom monocytoid dendritic cells are activated by ECP and Th1/Th2 ratios are shifted in favor of Th1, it may be that the net effect of ECP is to restore immune homeostasis. In CTCL, the secretion of Th2 cytokines by leukemia cells inhibits, in a paracrine fashion, a Th1-mediated anti-tumor response, and ECP induces a shift toward Th1 cyokine secretion by inducing apoptosis of tumor cells and thus, enhanced processing and tumor antigen recognition. In the context of the immune dysregulation of cGVHD,with ongoing auto and alloreactivity, the net inhibitory effect of ECP on both activated T cells and antigen presenting cells favors attenuation of ongoing Th1-mediated events, thereby removing the inhibition to Th2 cytokine secretion and restoring the Th1/Th2 balance. This selective effect on Th1 57 The effects of ECP on dendritic cell function and Th1/Th2 subsets will be further explored in a randomized clinical trial of ECP vs conventional immunosuppressive therapy in patients with cGVHD. This trial will enroll patients with steroid refractory or steroid-dependent cGVHD with skin manifestations. Patients will be given immunosuppressive agents (FK506, CSA) with a total of 25 ECP treatments over 12 weeks in the treatment arm or immunosuppressive therapy alone in the control arm. The efficacy endpoint will be improvement in skin GVHD.
Because of its effects on lymphocyte populations and dendritic cell function, ECP may play a role as a prophylactic modality in the prevention of GVHD in high risk patients. A recent pilot study using ECP prior to low-dose TBI and allogeneic stem cell infusion has reported a significant attenuation of aGVHD with preserved graft-versusdisease effect. 58 Further studies of the immunomodulatory effects of ECP in the setting of both acute and chronic GVHD, as well as in host conditioning prior to allogeneic stem cell transplantation are needed to further understand the mechanism of action and optimal utilization of this novel therapeutic intervention in transplantation strategies.
